BiotechTube
Levicept

Levicept

London, United Kingdom· Est.
levicept.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.5M

Overview

Levicept is a private, clinical-stage biotech developing LEVI-04, a novel p75NTR-Fc fusion protein that inhibits neurotrophin-3 to treat chronic pain. The drug has successfully completed a Phase II trial in osteoarthritis knee pain, meeting all endpoints with a favorable safety profile, notably showing no rapid joint deterioration—a key differentiator from anti-NGF therapies. Backed by experienced leadership and venture capital from Medicxi, the company is positioned to advance its lead program into later-stage development and explore expansion into other pain indications.

Chronic PainOsteoarthritis

Technology Platform

p75 neurotrophin receptor (p75NTR)-Fc fusion protein platform designed to modulate the neurotrophin pathway, primarily by inhibiting neurotrophin-3 (NT-3) to restore neurotrophin homeostasis and provide analgesia.

Funding History

2
Total raised:$14.5M
Series A$12M
Seed$2.5M

Opportunities

The massive, underserved global market for osteoarthritis pain presents a blockbuster opportunity for a safe, effective, non-opioid therapy.
LEVI-04's favorable Phase II safety profile, specifically the absence of rapid joint deterioration, positions it as a potential best-in-class biologic to fill the gap left by failed anti-NGF therapies.
The platform's mechanism also offers substantial potential for expansion into other chronic pain indications, such as neuropathic pain or chronic low back pain.

Risk Factors

Key risks include the inherent uncertainty of Phase III clinical trials, where efficacy may not hold or new safety signals could emerge.
The company faces regulatory scrutiny given the historical safety issues with the related anti-NGF class and requires significant capital to fund late-stage development, creating financial and execution risk.

Competitive Landscape

Levicept competes in the chronic pain space against generic NSAIDs and opioids, newer anti-NGF antibodies (which have safety warnings), and other novel mechanisms in development. Its primary competitive advantage is LEVI-04's unique mechanism targeting NT-3, which has demonstrated analgesia without the rapid joint destruction associated with anti-NGFs, potentially offering a superior safety profile.

More companies in Biologics / Biosimilars →More companies in United Kingdom →